DAINIP S'TOMO PHARM (DPM BE) stock market data APIs
€9.6429
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
DAINIP S'TOMO PHARM Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for DPM.BE.
Prev. Close
9.6429
Open
9.6429
High
9.6429
Low
9.6429
52 wk Range
2.94-10.2
Market Cap
4 143 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get DAINIP S'TOMO PHARM data using free add-ons & libraries
Get DAINIP S'TOMO PHARM Fundamental Data
DAINIP S'TOMO PHARM Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DAINIP S'TOMO PHARM News
New
Central Bank, Tech Outlooks Lift Asian Stock Markets
Asian stock markets rallied on Wednesday after fresh record highs overnight on Wall Street, and on r PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
US Jobs, Federal Reserve Outlooks Lift Asian Stock Markets
Asian stock markets gained ground on Friday after recent soft US jobs market reports bolstered outlo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass., July 3...
Trade, Central Bank Outlooks Mix Asian Stock Markets
Asian stock markets finished unevenly Wednesday on the China-US trade outlook and ahead of central b PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
